Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct;4(5):1079-84.
doi: 10.2147/tcrm.s3123.

Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis

Susan S Baker  1
Affiliations

Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis

Susan S Baker. Ther Clin Risk Manag. 2008 Oct.

Abstract

Pancreatic enzyme replacement therapy (PERT) is the only treatment for malabsorption in cystic fibrosis (CF) caused by pancreatic insufficiency (PI). PI occurs in approximately 85% of patients with CF. PERT overcomes some, but not all the signs and symptoms of malabsorption. Clinical parameters such as growth, abdominal pain, diarrhea and gassiness, commonly used to adjust PERT dosing, are shown not to be good indicators of their effectiveness. The FDA does not provide oversight of preparations of pancreatic enzymes consistent with the oversight it provides for all other drugs. The FDA intends to rectify this situation. Measures of the effectiveness of PERT are limited to the coefficient of fat absorption, a difficult and unpleasant exercise for patients.

Keywords: cystic fibrosis; malabsorption; pancreatic enzymes; pancrelipase.

PubMed Disclaimer

References

    1. Apley J, Naish N. Recurrent abdominal pain: a field survey of 1,000 school children. Arch Dis Child. 1958;33:165–70. - PMC - PubMed
    1. Baker SS, Borowitz D, Duffy L, et al. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J Pediatr. 2005;146:189–93. - PubMed
    1. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc. 2001;101:438–42. - PubMed
    1. Borowitz DS, Grand RJ, Durie PR. Consensus Committee. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr. 1995;127:681–4. - PubMed
    1. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246–59. - PubMed